Plain-English translation of NCT06478927 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is a clinical trial testing palbociclib, a medication designed to slow cancer cell growth, in patients with advanced hepatocellular carcinoma (liver cancer) that has not responded to or become unmanageable with prior treatments. You would take the medication by mouth once daily while researchers monitor how well it works and track any side effects. The study aims to enroll 22 patients total.
Many patients with advanced liver cancer run out of effective treatment options after their first or second line of therapy fails. This trial is exploring whether this medication might offer a new option for those patients who have limited alternatives.
You likely qualify if…
You likely don't qualify if…
You would visit the trial clinic regularly to take by mouth once daily. The research team would monitor your health with blood tests, imaging scans, and physical exams to see if your cancer is responding and to watch for any side effects. The trial does not specify a set end date, but participants would typically continue until the medication stops working, they experience unmanageable side effects, or they decide to withdraw.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China